ArticleJournal of the American Veterinary Medical Association2023
Clinical and epidemiologic features of SARS-CoV-2 in dogs and cats compiled through national surveillance in the United States.
Article in Journal of the American Veterinary Medical Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Assessment of the Risk Impact of SARS-CoV-2 Infection Prevalence between Cats and Dogs in America and Europe: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2024Pooled it
- Active surveillance reveals common SARS-CoV-2 infections among cats and dogs from households with human COVID-19 cases in Texas, USA.One health (Amsterdam, Netherlands) · 2026Article
- First report of SARS-CoV-2 co-infection with chronic dermatophytosis in a lion (Panthera leo) ex situ at Colombia.BMC veterinary research · 2026Article
- SARS-CoV-2 at the human-pet interface: transmission and pre-existing immunity in pets within infected households.Frontiers in veterinary science · 2026Article
- Nationwide seroprevalence of SARS-CoV-2 Delta variant and five Omicron sublineages in companion cats and dogs in the USA: insights into their role in COVID-19 epidemiology.Emerging microbes & infections · 2025Article
- ACE2 Receptor Usage across Animal Species by SARS-CoV-2 Variants.Emerging infectious diseases · 2025Article
- Evaluating the distribution and clustering of SARS-CoV-2 antibodies in dogs across the United States of America.Scientific reports · 2025Article
- High SARS-CoV-2 Exposure in Feline Residents of a Cat Café in Texas, United States, 2021-2022.Veterinary sciences · 2025Article
- Surveillance of SARS-CoV-2 in Pets of Harris County, Texas, Revealed More Common Pet Infections in Households With Human COVID-19 Cases.Veterinary medicine and science · 2025Article
- A One Health Zoonotic Vector Borne Infectious Disease Family Outbreak Investigation.Pathogens (Basel, Switzerland) · 2025Article
- SARS-CoV-2 Mu variant in dogs visiting veterinary clinics during the third pandemic peak in Eastern Colombia.Veterinary research communications · 2024Article
- The Transmission of SARS-CoV-2 from COVID-19-Diagnosed People to Their Pet Dogs and Cats in a Multi-Year Surveillance Project.Viruses · 2024Article
- Investigation of SARS-CoV-2 Infection among Companion Animals in Households with Confirmed Human COVID-19 Cases.Pathogens (Basel, Switzerland) · 2024Article
- A Comprehensive Study of Cellular and Humoral Immunity in Dogs Naturally Exposed to SARS-CoV-2.Transboundary and emerging diseases · 2024Article
- SARS-CoV-2 surveillance in a veterinary health system provides insight into transmission risks.Journal of the American Veterinary Medical Association · 2024Article
- Article
- SARS-CoV-2 in Domestic UK Cats from Alpha to Omicron: Swab Surveillance and Case Reports.Viruses · 2023Article
- Neutralizing Antibodies against the SARS-CoV-2 Ancestral Strain and Omicron BA.1 Subvariant in Dogs and Cats in Mexico.Pathogens (Basel, Switzerland) · 2023Article
- A SARS-CoV-2: Companion Animal Transmission and Variants Classification.Pathogens (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo characterize clinical and epidemiologic features of SARS-CoV-2 in companion animals detected through both passive and active surveillance in the US. ANIMALS: 204 companion animals (109 cats, 95 dogs) across 33 states with confirmed SARS-CoV-2 infections between March 2020 and December 2021. PROCEDURES: Public health officials, animal health officials, and academic researchers investigating zoonotic SARS-CoV-2 transmission events reported clinical, laboratory, and epidemiologic information through a standardized One Health surveillance process developed by the CDC and partners.
resultsAmong dogs and cats identified through passive surveillance, 94% (n = 87) had reported exposure to a person with COVID-19 before infection. Clinical signs of illness were present in 74% of pets identified through passive surveillance and 27% of pets identified through active surveillance. Duration of illness in pets averaged 15 days in cats and 12 days in dogs. The average time between human and pet onset of illness was 10 days. Viral nucleic acid was first detected at 3 days after exposure in both cats and dogs. Antibodies were detected starting 5 days after exposure, and titers were highest at 9 days in cats and 14 days in dogs. CLINICAL RELEVANCE: Results of the present study supported that cats and dogs primarily become infected with SARS-CoV-2 following exposure to a person with COVID-19, most often their owners. Case investigation and surveillance that include both people and animals are necessary to understand transmission dynamics and viral evolution of zoonotic diseases like SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.